

Date: 21 May 2026

To

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544293

The Secretary
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra -Kurla Complex, Bandra (East)
Mumbai- 400 051
Scrip Symbol : SURAKSHA

Dear Sir / Ma'am,

Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Sub: Press release in respect of audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2026.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated 14 July 2023, and NSE's Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under:

Date of occurrence of Event/Information: 21 May 2026
Time of occurrence of Event/Information: 5:30 p.m. (IST)

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

Mamta Jain

Company Secretary & Compliance Officer


Encl: As above

Healthy Growth in Test Volumes and Realizations Drives FY26 Earnings

*Total Income grew by 25% year-on-year and
EBITDA grew by 26% year-on-year in Q4FY26*

Kolkata, 21st May 2026: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and full year ended 31st March 2026.

FY26 Financial Performance Snapshot (Y-o-Y)



Key Financial Highlights

Particulars	Q4 FY26	Q4 FY25	Y-o-Y	FY26	FY25	Y-o-Y
Total Income (₹ million)	821.97	659.12	24.7%	3135.78	2559.39	22.5%
EBTIDA (₹ million)	251.55	200.05	25.7%	985.58	850.88	15.8%
EBTIDA Margin (%)	30.9%	30.7%		31.8%	33.8%	
PAT (₹ million)	61.59	71.71	-14.1%	314.04	309.78	1.4%
PAT Margin (%)	7.6%	11.0%		10.1%	12.3%	

Key Operational Highlights

Particulars	Q4 FY26	Q4 FY25	Y-o-Y	FY26	FY25	Y-o-Y
Total tests (# million)	1.97	1.82	8.2%	8.16	6.68	22.0%
Total Patients (# million)	0.30	0.29	1.7%	1.37	1.19	14.9%
Tests per patient (#)	6.57	6.17	6.4%	5.95	5.60	6.2%
Average Revenue per test (₹)	421	356	15.6%	381	377	0.9%
Average Revenue per patient (₹)	2,706	2,201	23%	2,264	2,113	7.1%

Commenting on the results Mrs. Ritu Mittal, Joint Managing Director & CEO said, -

“We concluded FY26 on a strong note, delivering healthy top-line growth driven by sustained momentum in our network expansion and improving market presence.

The EBITDA margin continues to reflect investments towards newly launched centres and expansion initiatives. Our centres which are >2 years old continue to operate at a stable 36–37% EBITDA margin, demonstrating the resilience of our business model. We remain focused on ‘Investing for Scale: Short-term Compression for Long-term Value Creation.’

During FY26, we significantly expanded our footprint by adding 2 hubs, 11 spoke centres and 4 PPP, strengthening our reach and accessibility across key markets. Also, our recently launched genomic lab has picked up very well.

Going forward, we remain committed to driving higher utilization across new centres, enhancing operational efficiencies, and delivering sustainable growth while creating long-term value for our shareholders..”

About Suraksha Diagnostic Limited:

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar and Assam.

The company’s central reference laboratory is accredited by the College of American Pathologists, while the 4 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centres are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Company: Suraksha Diagnostic Limited	Investor Relations: MUFG Intime India Private Limited
Email: investors@surakshanet.com	Name: Mr. Omkar Bagwe Email: omkar.bagwe@in.mpms.mufg.com
CIN: L85110WB2005PLC102265	Name: Sumeet Khaitan Email: Sumeet.khaitan@in.mpms.mufg.com
Website: https://www.surakshanet.com/	Meeting Request Link – Click Here

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company’s operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.